Brief: Xoma Corp Novartis International Pharma Discontinuing Phase 3 Trial Investigating NIS793
18/07/2023 14:25
July 18 (Reuters) - XOMA Corp XOMA.O :
* XOMA CORP: NOVARTIS INTERNATIONAL PHARMA DISCONTINUING
PHASE 3
TRIAL INVESTIGATING NIS793 IN FIRST-LINE METASTATIC PANCREATIC
DUCTAL ADENOCARCINOMA
Further company coverage: XOMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xoma Royalty
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM